(Shanghai/Suzhou/Beijing, China) Duality Biologics ("Duality") recently reached a strategic cooperation agreement with Sinotau Pharmaceuticals ("Sinotau"). According to the agreement, Sinotau will grant the self-developed preferred monoclonal antibody for specific tumor targets to Duality for the exclusive development of ADC medicines in the world. Based on the DITAC (Duality Immune Toxin Antibody Conjugate) technology platform with its independent intellectual property rights, Duality will rapidly develop the world's best-in-class ADC medicines to benefit patients all over the world. And Sinotau will receive the down payment, milestone payments and sales-based royalties paid by Duality.

Sinotau and Duality always maintain a strategic win-win cooperative relationship. Before signing the agreement, we have realized the POC verification, and in future both parties will continue to uphold the common goal of rapid research and development of high-quality ADC: Duality will be responsible for the preclinical research, clinical development, clinical registration, production and commercialization of the ADC candidate molecule; Sinotau will continue to pay close attention to the relevant follow-up research of this molecule and provide necessary support.

"Since its establishment, Sinotau has set a vision and goal of benefiting the majority of patients. We are very pleased to have established a strategic partnership with Duality. Through this cooperation, we can further show the technical level and advantages of both sides and will continue to pay attention to the further progress of the project. Based on the technology from Duality's DITAC platform, we look forward to seeing this project to be promoted to clinic as soon as possible to benefit patients all over the world.” Said Ms. Tang Yanmin, CEO of Sinotau pharmaceuticals.

“I'm very pleased to achieve strategic collaboration with Sinotau, and we are both very excited and confident about this new target of ADC drug. The combination of our proprietary ADC platform in next-generation and tumor-specific antibody will optimize the value of our DITAC platform, a leading 3rd generation toxin ADC platform with significantly improved therapeutic window, and rapidly enrich our pipeline to generate original innovative products. The signing of this agreement is the beginning of our platform-based strategic win-win cooperation. In the future, Duality hopes to maintain the close cooperation with Sinotau and continue to propel more product development, jointly bringing better therapeutics to patients.” said Dr. John Zhu, founder and CEO of Duality.

About Sinotau Pharmaceuticals

Sinotau Pharmaceutical Group was founded in 2005. Through years of R&D efforts the company has developed three clear scopes within the Group, a generic pharma arm, an innovative biological initiative and a nuclear medicine (Radiopharmaceutical) enterprise. Sinotau plans to build radiopharmaceutical sites in Jiangsu province, Guangdong province and Sichuan province, among other places, to ensure distribution to the majority of the Chinese market. This network of facilities will integrate manufacturing and labelling of leading nuclear medicine products, training, R&D and international cooperation activities. All sites will be in line with cGMP standards. Sinotau looks into the future following the company's mission "in pursuit of healthier lives", and through continued investments in R&D. Sinotau is developing a solid portfolio of novel products to improve the quality of life of patients. And to contribute to the development of China's radiopharmaceutical sector.

About Duality Biologics

"To Translate Novel Modality into Reality". Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Biologics is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on novel technology platforms and innovative medicines for cancer and autoimmune diseases, Duality Biologics has successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights.  These include DITAC (Duality Immune Toxin Antibody Conjugate), DIMAC (Duality Immune Modulating Antibody Conjugate) and DISAC (Duality Immune Stimulating Antibody Conjugate).  Duality Biologics has successfully built a robust pipeline of more than 10 best-in-class and/or first-in-class ADC programs, of which several drug candidates are in the IND stage. Duality Biologics will continue to establish rich product pipelines to benefit patients through the independent research and strategic collaboration.